Document is current
Any future updates will be listed below
-
Authors
Apperley, Jane F. https://orcid.org/0000-0002-1710-1794
Milojkovic, Dragana
Cross, Nicholas C. P. https://orcid.org/0000-0001-5481-2555
Hjorth-Hansen, Henrik https://orcid.org/0000-0002-2670-5696
Hochhaus, Andreas
Kantarjian, Hagop https://orcid.org/0000-0002-1908-3307
Lipton, Jeffrey H.
Malhotra, Hemant
Niederwieser, Dietger https://orcid.org/0000-0002-4737-1103
Radich, Jerald
Rousselot, Philippe https://orcid.org/0000-0003-3238-4494
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
Schiffer, Charles A.
Silver, Richard https://orcid.org/0000-0002-8524-0964
Soverini, Simona https://orcid.org/0000-0002-4508-0353
Stenke, Leif
Turkina, Anna https://orcid.org/0000-0001-9947-2371
Casado, Luis Felipe
Castagnetti, Fausto https://orcid.org/0000-0002-0602-2628
Cervantes, Francisco
Clark, Richard E. https://orcid.org/0000-0002-1261-3299
Cortes, Jorge https://orcid.org/0000-0002-8636-1071
Deininger, Michael https://orcid.org/0000-0002-2987-1331
Hughes, Timothy P. https://orcid.org/0000-0002-0910-3730
Janssen, Jeroen
Jiang, Qian https://orcid.org/0000-0001-7131-0522
Kim, Dong-Wook https://orcid.org/0000-0003-3967-4267
Larson, Richard A. https://orcid.org/0000-0001-9168-3203
Mahon, Francois X.
Mauro, Michael https://orcid.org/0000-0002-2251-4032
Mayer, Jiri https://orcid.org/0000-0003-0567-9887
Nicolini, Franck E.
Pane, Fabrizio
Rea, Delphine
Richter, Johan https://orcid.org/0000-0002-0374-6823
Rosti, Gianantonio
Saglio, Giuseppe https://orcid.org/0000-0002-1046-3514
Hehlmann, Rüdiger
- License Information
-
More Information
Article History
Received: 29 May 2025
Revised: 3 June 2025
Accepted: 10 June 2025
First Online: 11 July 2025
Competing interests
: JFA received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Incyte, Novartis, Paladin and Terns, and institutional research support from Incyte and Pfizer. DM received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Enliven, Incyte, Novartis and Terns, and institutional research support from Ascentage, Incyte and Pfizer. NCPC received honoraria for advisory boards/consultancies/speakers bureau from Blueprint and Novartis, and institutional research support from Novartis. HHH received honoraria for advisory boards/consultancies/speakers bureau from Incyte and institutional research support from Austrian Orphan, BMS/Celgene, Incyte and Pfizer. AH received honoraria for advisory boards/consultancies/speakers bureau from Enliven, Incyte and Novartis and institutional research support from BMS, Enliven, Incyte, Novartis, Pfizer and Terns. HK received honoraria for advisory boards/consultancies/speakers bureau from AbbVie, Amgen, Ascentage, Takeda, Novartis and Pfizer and institutional research support from AbbVie, Amgen, Ascentage, BMS/Celgene, Daiichi Sankyo, Ipsen Biopharmaceuticals, Immunogen, KAHR Medical, Novartis, Shenzhen Target Rx and Stemline. JHL received honoraria for advisory boards/consultancies/speakers bureau from Takeda and Pfizer. HM received honoraria for advisory boards/consultancies/speakers bureau from Astra Zeneca, BARD India, Cipla, Eli Lilly, NATCO, Omnicuris, Novartis, Pfizer and Roche. DN has no disclosures. JR has no disclosures. PR received institutional research support from Incyte and Pfizer. SSa received honoraria for advisory boards/consultancies/speakers bureau from Incyte, Novartis, Roche and Zentiva and institutional research support from BMS/Celgene, Incyte and Novartis. CAS has no disclosures. RTS has no disclosures. SSo received honoraria for advisory boards/consultancies/speakers bureau from Incyte and Novartis. LS received institutional research support from Xspray Pharma. AT received honoraria for advisory boards/consultancies/speakers bureau from Novartis, Pfizer and R Pharm. LFC received honoraria for advisory boards/consultancies/speakers bureau from Incyte, Novartis and Pfizer. FCa received honoraria for advisory boards/consultancies/speakers bureau from BMS/Celgene, Incyte, Novartis, Pfizer and Zentiva and institutional research support from BMS/Celgene, Incyte, Novartis and Pfizer. FCe has no disclosures. REC has no disclosures. JC received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Biopath Holdings, Enliven, Takeda, Janssen, Syndax, Novartis, Pfizer, SunPharma and Terns and institutional research support from Ascentage, Cyto agents, Takeda, Kuro Oncology, Novartis, SunPharma and Terns. MD received honoraria for advisory boards/consultancies/speakers bureau from Blueprint, Cogent, Takeda, Novartis and Pfizer and institutional research support from Terns. TPH received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Enliven, Takeda, Novartis and Terns and institutional research support from Novartis. JJ received institutional research support from BMS/Celgene and Novartis. QJ received honoraria for advisory boards/consultancies/speakers bureau from Ascentage and Novartis. DWK received honoraria for advisory boards/consultancies/speakers bureau from Enliven, ILYANG, Novartis, Terns Pharma: RAL, CVS/Caremark, Daiichi Sankyo, Epizyme/Ipsen, Takeda and Novartis, and institutional research support from BMS/Celgene, Enliven, ILYANG, Takeda, Novartis, Otsuka and Terns. RAL received institutional research support from Ascentage, Astellas, Biomea Fusion, Cellectis, Daiichi Sankyo and Novartis. FXM received honoraria for advisory boards/consultancies/speakers bureau from Incyte and Novartis. MJM received honoraria for advisory boards/consultancies/speakers bureau from AbbVie, BMS, Enliven, Takeda, Novartis, Pfizer and Terns, and institutional research support from BMS/Celgene, Enliven, Takeda, Novartis and Terns. JM received institutional research support from BMS/Celgene and Novartis. FEN received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, BMS/Celgene, GSK, Incyte, Kumquat sciences Inc, Novartis and Terns and institutional research support from Incyte and Novartis. FP received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, BMS/Celgene, Incyte, Novartis and Pfizer. DR received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Enliven, Incyte, Novartis and Terns. JRi has no disclosures. GR received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Incyte, Novartis and Pfizer. GS received honoraria for advisory boards/consultancies/speakers bureau from Ascentage, Enliven, Hikma and Novartis. RH has no disclosures
